DGAP-News: Evotec SE / Key word(s): Miscellaneous 
EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES 
 
2021-01-07 / 15:49 
The issuer is solely responsible for the content of this announcement. 
 
*Hamburg, Germany, 07 January 2021:* 
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) 
announced today that its management will be presenting at and attending the 
following upcoming conferences in the first quarter of 2021: 
 
*J.P. Morgan 39th Annual Healthcare Conference 2021* 
 
? *Date*: Monday, 11 January - Thursday, 14 January 2021 
Presentation: Tuesday, 12 January, 7.30 am EST (1.30 pm CET, 12.30 pm GMT, 
4.30 am PST) 
 
? *Venue*: Virtual 
 
? *Attendee*: Werner Lanthaler, Chief Executive Officer 
 
*Commerzbank German Investment Seminar * 
 
? *Date*: Wednesday, 13 January 2021 
 
? *Venue*: Virtual 
 
? *Attendee*: Werner Lanthaler, Chief Executive Officer 
 
*UniCredit Kepler Cheuvreux German Corporate Conference* 
 
? *Date*: Wednesday, 20 January 2021 
Presentation: Wednesday, 20 January, 12 pm CET 
 
? *Venue*: Virtual 
 
? *Attendee: * Werner Lanthaler, Chief Executive Officer 
 
*BioCapital Europe* 
 
? *Date*: Thursday, 11 March 2021 
 
? *Venue*: Virtual 
 
? *Attendee*: Enno Spillner, Chief Financial Officer 
 
ABOUT EVOTEC SE 
Evotec is a drug discovery alliance and development partnership company 
focused on rapidly progressing innovative product approaches with leading 
pharmaceutical and biotechnology companies, academics, patient advocacy 
groups and venture capitalists. We operate worldwide and our more than 3,400 
employees provide the highest quality stand-alone and integrated drug 
discovery and development solutions. We cover all activities from 
target-to-clinic to meet the industry's need for innovation and efficiency 
in drug discovery and development (EVT Execute). The Company has established 
a unique position by assembling top-class scientific experts and integrating 
state-of-the-art technologies as well as substantial experience and 
expertise in key therapeutic areas including neuronal diseases, diabetes and 
complications of diabetes, pain and inflammation, oncology, infectious 
diseases, respiratory diseases, fibrosis, rare diseases and women's health. 
On this basis, Evotec has built a broad and deep pipeline of more than 100 
co-owned product opportunities at clinical, pre-clinical and discovery 
stages (EVT Innovate). Evotec has established multiple long-term alliances 
with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, 
CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For 
additional information please go to www.evotec.com [1] _and follow us on 
Twitter_ @Evotec [2]_._ 
 
_FORWARD LOOKING STATEMENTS_ 
Information set forth in this press release contains forward-looking 
statements, which involve a number of risks and uncertainties. The 
forward-looking statements contained herein represent the judgement of 
Evotec as of the date of this press release. Such forward-looking statements 
are neither promises nor guarantees, but are subject to a variety of risks 
and uncertainties, many of which are beyond our control, and which could 
cause actual results to differ materially from those contemplated in these 
forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such 
statements to reflect any change in our expectations or any change in 
events, conditions or circumstances on which any such statement is based. 
 
IR Contact Evotec SE: 
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: 
+49.(0)40.56081-775, volker.braun@evotec.com 
 
2021-01-07 Dissemination of a Corporate News, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     Evotec SE 
             Manfred Eigen Campus / Essener Bogen 7 
             22419 Hamburg 
             Germany 
Phone:       +49 (0)40 560 81-0 
Fax:         +49 (0)40 560 81-222 
E-mail:      info@evotec.com 
Internet:    www.evotec.com 
ISIN:        DE0005664809 
WKN:         566480 
Indices:     MDAX, TecDAX 
Listed:      Regulated Market in Berlin, Frankfurt (Prime Standard); 
             Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, 
             Munich, Stuttgart, Tradegate Exchange 
EQS News ID: 1159160 
 
End of News DGAP News Service 
 
1159160 2021-01-07 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=d9f30c4aeb65d3276d5bd878be7dc75c&application_id=1159160&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b578791509083b40bb44fb801a96a7b5&application_id=1159160&site_id=vwd&application_name=news

(END) Dow Jones Newswires

January 07, 2021 09:49 ET (14:49 GMT)